anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a thermally treated Schizandra chinensis (Omija) which is excellent in functional and antibacterial activities, and a method for producing the same. More specifically, the thermally treated Schizandra chinensis is produced by sealing Schisandra chinensis, from which foreign matter is removed, in a container and thermally treating the same at a high temperature of 80 to 90°C for 5 to 8 days. In the method of producing Schizandra chinensis according to the present invention, the Schizandra chinensis is put in a sealed container and then heated and manufactured at 80 to 90°C for 5 to 8 days and, unlike conventional hot air drying and high temperature steaming (superheated steam treatment) processes, the Schisandra chinensis by the present invention can be produced without the loss of moisture and volatile components, the deterioration of sensory function, and the loss of useful components. The Schizandra chinensis juice produced by the method has more excellent functionalities and broader antibacterial activities than fresh Schizandra chinensis juice. In particular, the present invention is efficient by being applied without any separate hydration process since there is no moisture loss by being produced in a sealed condition. The sealed and thermally treated Schizandra chinensis of the present invention is produced in various forms such as extract, powder, pill, tablet, etc. to have excellent effects capable of being made in various forms which can be taken at any time, thereby being useful in various industries such as pharmaceutical industry, food industry and cosmetics industry.
The invention discloses a pharmaceutical composition containing total saponins and total alkaloids of caulophyllum robustum. The total saponins and total alkaloids of the caulophyllum robustum serve as active ingredients, and are in the mass ratio of (1:10)-(1:100). The total saponins and total alkaloids of the caulophyllum robustum are combined organically, thereby achieving the effects of dispelling wind, eliminating dampness, resisting inflammation and relieving pain. As proved by experiments, the composition has an inhibiting effect on anti-non-specific and specific inflammation models, and has a strong pain relieving effect. The apoptosis rate of RA (Rheumatoid Arthritis) rat synovial cells can be increased remarkably, thereby preventing joints from being further damaged, effectively treating rheumatoid arthritis and achieving good inflammation resisting and immunoregulation effects. Moreover, a synergistic effect is achieved by combining alkaloids with saponin compounds. Being different from a Chinese medicinal compound prepared on the basis that decoction pieces are combined, the composition is more definite in chemical ingredients of which over 50 percent can be qualified and quantified accurately, thereby easily performing quality control and meeting the requirements of the modern pharmaceuticals industry.
In the current study, the investigators are examining the use of a mobile electronic application used to deliver cognitive rehabilitation tasks to patients with mild cognitive impairment due to Alzheimer's disease, and patients with mild Alzheimer's disease. An estimated 100 patients will be enrolled into the study (\~50 patients with mild cognitive impairment, \~50 patients with Alzheimer's disease).

Participants will either receive memory tasks designed to help stabilize or improve memory (Intervention Group) or a set of word or math puzzles (Control Group). Participants will complete memory tasks or puzzles for a six month period. The investigators will conduct pre- and post- neuropsychological testing to assess changes in cognitive status (e.g., memory, language, executive functioning) in the intervention group. Neuropsychological tests assessing changes to cognition will be completed prior to participant assignment to the Intervention or Control Group. Both groups will then be assessed again using neuropsychological tests. The investigators will also assess changes in performance on cognitive rehabilitation tests over the six month period to determine the efficacy of these tasks.
Teratogenic Effects - Pregnancy Category C

Venlafaxine did not cause malformations in offspring of rats or rabbits given doses up to 2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m basis. However, in rats, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation, when dosing began during pregnancy and continued until weaning. The cause of these deaths is not known. These effects occurred at 2.5 times (mg/m ) the maximum human daily dose. The no effect dose for rat pup mortality was 0.25 times the human dose on a mg/m basis. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 222
A sample slide for holding a tissue sample and a method of loading a tissue sample onto a sample slide are described. The sample slide may be printed with control information and patient information corresponding to the respective control tissue sample and patient tissue sample mounted on the sample slide. The control information and patient information may be printed at different times. The control information may be printed prior to loading the control tissue sample onto the sample slide, and the patient information may be printed after loading the control tissue sample onto the sample slide. The control information and patient information may be encoded in a first bar code and a second bar code, respectively. The bar codes may have different configurations, such as different bar code types or different orientations. Other embodiments are described and claimed.
During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support.54 cm.
The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
PURPOSE:To provide a calcitonin agent for transnasal administration, having improved absorption efficiency of the calcitonin through the mucosa of nasal cavity by the use of aldose and/or glucosamine as an adsorbefacient without causing the side effects such as the tissue damage, etc., and useful for the remedy of osteoporosis, etc. CONSTITUTION:The objective drug composition for transnasal administration contains (A) a calcitonin useful for the remedy of osteoporosis, hypercalcemia, Behcet's disease, etc. such as salmon calcitonin, human calcitonin, elcatonin, swine calcitonin, etc. and (B) an aldose (especially ribose or glucose) and/or glucosamine as an absorbefacient. The active components are added to a liquid diluent or carrier suitable for the administration to the nasal mucosa. The agent is formed in the form of aqueous solution, hydrogel or solid powder having high absorption efficiency through the nasal mucosa and free from the side effects such as the damage of tissue, etc.
The study will employ a 3+3 design and include 3 treatment cohorts. In each cohort, patients will receive 6 cycles of AVD and 12 doses of nivolumab. In this cohort, patients will receive nivolumab in combination with AVD during cycles 5 and 6 only, followed by 8 additional doses of nivolumab. In subsequent cohorts, nivolumab will be combined with increasing numbers of cycles of AVD. Based upon safety data from another study with Nivolumab, we will no longer need to evaluate dose level 2. If we determine that dose level 1 is safe, the next group of patients will enroll onto dose level 3. Prophylactic growth factor support is mandatory for all patients on Cohort B and should be used per the treating physician's discretion for all other patients.
The transcutaneous electrical acupoint stimulator applied alternating current (including sine wave, pulse wave and modulation wave) with frequency of 2 \~ 100Hz and intensity of 10-20mA to stimulate corresponding acupoints through skin electrodes. The stimulated acupoints include Hegu acupoints, Luogong acupoints, Neiguan acupoints and Waiguan acupoints.
PURPOSE: To efficiently produce high quality sugar syrup, etc., from the peels of citrus fruits. CONSTITUTION: A soln. contg. a water-miscible nonaq. solvent selected from among lower alcohol, lower ketone, mono- and dialkyl esters of ethylene glycol is fed into a solvent extraction region and the peels of citrus fruits are subjected to countercurrent solvent extraction with the soln. for a sufficiently long time to obtain an aq. liq. extract contg. practically all of sugar, essential oil and bioflavonoids existing in the peels. The essential oil contained in the resultant extract is insolubilized by diluting the extract with an aq. diluent and the insolubilized essential oil is separated from the extract. The bioflavonoids existing in the extract are then insolubilized by removing the nonaq. solvent from the extract and the insolubilized bioflavonoids are separated from the extract. The remaining extract is refined to obtain the objective sugar syrup product.
Pharmacokinetics of AVONEX in multiple sclerosis patients have not been evaluated. The pharmacokinetic and pharmacodynamic profiles of AVONEX in healthy subjects following doses of 30 micrograms through 75 micrograms have been investigated. Serum levels of AVONEX as measured by antiviral activity are slightly above detectable limits following a 30 microgram intramuscular dose, and increase with higher doses. 

After an intramuscular dose, serum levels of AVONEX generally peak at 15 hours post-dose (range: 6-36 hours) and then decline at a rate consistent with a 19 (range: 8-54) hour elimination half-life. 

Subcutaneous administration of AVONEX should not be substituted for intramuscular administration as there is no data establishing that subcutaneous and intramuscular administration of AVONEX result in equivalent pharmacokinetic and pharmacodynamic parameters. 

Biological response markers (e.g., neopterin and β2-microglobulin) are induced by AVONEX following parenteral doses of 15 micrograms through 75 micrograms in healthy subjects and treated patients. Biological response marker levels increase within 12 hours of dosing and remain elevated for at least 4 days. Peak biological response marker levels are typically observed 48 hours after dosing. The relationship of serum AVONEX levels or levels of these induced biological response markers to the mechanisms by which AVONEX exerts its effects in multiple sclerosis is unknown.
PURPOSE: Over the past decade, the Amazon basin has faced numerous infectious epidemics. Our comprehension of the actual extent of these infections during pregnancy remains limited. This study aimed to clarify the clinical and epidemiological features of emerging and re-emerging infectious diseases during pregnancy in western French Guiana and along the Maroni River over the previous nine years.
METHODS: This retrospective cohort study enrolled pregnant women living in west French Guiana territory and giving birth in the only local referral center after 22 weeks of gestation between 2013 and 2021. Data on symptomatic or asymptomatic biologically confirmed emerging or re-emerging diseases during pregnancy was collected.
RESULTS: Six epidemic waves were experienced during the study period, including 498 confirmed Zika virus infections (2016), 363 SARS-CoV-2 infections (2020-2021), 87 chikungunya virus infections (2014), 76 syphilis infections (2013-2021), and 60 dengue virus infections (2013-2021) at different gestational ages. Furthermore, 1.1% (n = 287) and 1.4% (n = 350) of pregnant women in west French Guiana were living with HIV and HTLV, respectively. During the study period, at least 5.5% (n = 1,371) faced an emerging or re-emerging infection during pregnancy.
CONCLUSION: These results highlight the diversity, abundance, and dynamism of emerging and re-emerging infectious agents faced by pregnant women in the Amazon basin. Considering the maternal and neonatal adverse outcomes associated with these infections, increased efforts are required to enhance diagnosis, reporting, and treatment of these conditions.
3,3',4',4',5-Polychlorinated biphenyls (PCB126) is classified as a persistent organic environmental pollutant that can cause liver damage by producing excessive reactive oxygen species (ROS). ROS also can stimulate neutrophil extracellular traps (NETs) formation, which cause damage to organism if NETs are produced in excess. Melatonin is generally considered to possess strong antioxidant and anti-inflammation prosperities, but it is unclear whether it can alleviate PCB126-induced injury. To explore whether PCB126-induced liver injury is related to the formation of NETs and whether melatonin has a potent protective effect, we established PCB126 exposure/ PCB126 and melatonin co-treatment mouse models by gavage. To further clarify the specific mechanism, we also cultured neutrophils and AML12 cells to replicate in vivo model. Here, we found PCB126 exposure resulted in an elevation in the activities of MDA, LPO, PCO, and 8-OHdG, and a reduction in the activities of CAT, GSH-PX and SOD. We found that PCB126 exposure led to an elevation in the expression levels of chemokines (CCL2, CCL3, CCL4, CXCL12, and CXCL8) and marker factors for NETs formation (MPO, NE, NOX2, PKCα, and PKCζ) in the PCB126 group. IF, SYTOX staining, and SEM results also revealed that PCB126 could stimulate NETs formation. In addition, results of a co-culture system of PBNs and AML12 cells revealed that the expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) significantly decreased and the expression levels of metabolism factors (Fas, Acc, and Srebp) slightly decreased for scavenging NETs, indicating NETs formation aggravated PCB126-induced hepatic damages. Noteworthy, treatment with melatonin reversed these results. In summary, our findings revealed that melatonin alleviated hepatic damage aggravated by PCB126-induced ROS-dependent NETs formation through suppressing excessive ROS production. This finding not only enriches toxicological mechanism of PCB126, but more importantly extends biological effects of melatonin and its potential application values.
LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
BACKGROUND: Sympathetic hyperactivity plays an important role in the initiation and maintenance of pulmonary hypertension. Carotid baroreceptor stimulation (CBS) is an effective autonomic neuromodulation therapy. We aim to investigate the effects of CBS on hypoxia-induced pulmonary hypertension and its underlying mechanisms.
METHODS AND RESULTS: Rats were randomly assigned into 4 groups, including a Control-sham group (n=7), a Control-CBS group (n=7), a Hypoxia-sham group (n=10) and a Hypoxia-CBS group (n=10). Echocardiography, ECG, and hemodynamics examination were performed. Samples of blood, lung tissue, pulmonary arteries, and right ventricle were collected for the further analysis. In the in vivo study, CBS reduced wall thickness and muscularization degree in pulmonary arterioles, thereby improving pulmonary hemodynamics. Right ventricle hypertrophy, fibrosis and dysfunction were all improved. CBS rebalanced autonomic tone and reduced the density of sympathetic nerves around pulmonary artery trunks and bifurcations. RNA-seq analysis identified BDNF and periostin (POSTN) as key genes involved in hypoxia-induced pulmonary hypertension, and CBS downregulated the mRNA expression of BDNF and POSTN in rat pulmonary arteries. In the in vitro study, norepinephrine was found to promote pulmonary artery smooth muscle cell proliferation while upregulating BDNF and POSTN expression. The proliferative effect was alleviated by silence BDNF or POSTN.
CONCLUSIONS: Our results showed that CBS could rebalance autonomic tone, inhibit pulmonary arterial remodeling, and improve pulmonary hemodynamics and right ventricle function, thus delaying hypoxia-induced pulmonary hypertension progression. There may be a reciprocal interaction between POSTN and BDNF that is responsible for the underlying mechanism.
Prepn. for the prophylaxis of bovine trichophytis is produced by cultivating an immunogenic culture of Trichophyton foviformes on a solid or liquid nutrient medium at 26-28 degrees C for 12-15 days until optimal accumulation of the microconidia of the microorganism, then separating off the biomass, homogenizing the biomass to give a suspension of the individual cells, then separating off the end prod. (e.g. by dilution to a cell concentration of 6-9x 106 cells/ml with a sterile physiological solution or by lyophilization). The prepn. can be used for immunizing calves and adult cattle. It is non-injurious and causes no side-effects. Within about 1 month of immunization the animals have a high degree of immunity against natural and experimental infection with Trichophyton foviformes and this immunity lasts for at least 4 years.
Plasmid DNA encoding at least one Borrelia genospecies antigen and methods for making and using such a plasmid are disclosed and claimed. The genospecies can be burgdorferi, garinii and/or afzelli. The antigen can be OspA and/or OspB and/or OspC. Compositions containing the plasmid DNA are useful for administration to a host susceptible to Lyme Disease for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens in vitro. And, the inventive plasmid can be prepared by isolating DNA (such as DNA coding for: promoter, leader sequence, antigen, and terminator) and performing a ligation or ligations, such as a three-way ligation. More particularly, administration of DNA encoding Borrelia genospecies antigen, e.g., OspA and/or OspB and/or OspC and compositions therefor for eliciting an immunological response against Borrelia, such as a protective response preventive of Lyme Disease, are disclosed and claimed. Thus, Lyme Disease vaccines or immunological compositions, and methods of making and using them, are disclosed and claimed.
Introduction. Eighty percent of children with primitive nephrotic syndrome (NS) will have at least one relapse in their life. Specific risk factors could be associated with a higher incidence of relapses and a worse prognosis. This study aims to deepen the demographic and onset-related risk factors in children with known diagnosis of primitive NS attending the Pediatric Nephrology Unit of the University Hospital of Padua. Methods. Observational, descriptive study of all children (1-11 years old) with a known diagnosis of Primitive NS who attended our Pediatric Nephrology Unit between 1 January 2002 and 31 March 2023. Results. 49 patients were involved. 79.5% had at least one episode of NS relapse during their lifetime. 69.4% were classified as frequently relapsing or steroid-dependent NS. The relapse risk factor "non-Western ethnicity" was related to a worse prognosis and steroid-dependent NS classification (p = 0.041). The onset-related risk factor "thrombocytosis" appears to be related to a better prognosis (p = 0.03). Conclusion. The relapse risk factors "non-Western ethnicity" and "thrombocytosis" are characterized by worse and better prognosis, respectively. This evidence could support the follow-up of primitive NS in pediatric age.
Bivalent inhibitors having affinity for one or more dimeric GST isozymes are provided. The bivalent inhibitors comprise two ligand domains connected by a molecular linker, wherein the ligand domains have affinity for one or more monomers in the one or more dimeric GST isozymes. The ligand domains are separated by a distance ranging from about 5 to about 100 Å. The bivalent inhibitors of the invention demonstrate greatly improved affinity for GST isozymes. In a specific embodiment, the bivalent inhibitors of the invention further provide affinity for substantially one GST isozyme and for substantially one GST class. The bivalent inhibitors of the invention have numerous uses that include the treatment of drug-resistant cancer, malaria, and stimulation of hematopoiesis.
A surgical stapling instrument is disclosed. The surgical stapling instrument includes an anvil configured to clamp a tissue, a circular stapling head assembly comprising a first row of staples and a second row of staples, a first staple driver configured to drive the first row of staples, a second staple driver configured to drive the second row of staples, wherein the first and second staple drivers are independently actuatable. A motor is coupled to the anvil. The motor is configured to move the anvil between a first position and a second position. A control circuit coupled to the motor. The control circuit is configured to set a stroke length for the first and second staple drivers to a first length, detect a malformed staple in the first row of staples, and set the stroke length for the second staple driver to a second length.
This study seeks to establish the feasibility and acceptability of an alternative treatment strategy for uncomplicated acute bacterial skin and skin structure infection (ABSSSI) in the Barnes Jewish Hospital (BJH) Emergency Department (ED) focusing on hospital admission avoidance using single-dose, long-acting antimicrobial therapy complemented by close follow-up in the ambulatory setting. The extended half-life of these new antimicrobials (dalbavancin, oritavancin) allows for an effective treatment course of \>7 days with a single dose, which is the accepted duration for which ABSSSI is usually treated with daily doses of other intravenous or oral antimicrobials. The investigators believe that such an approach will conserve hospital resources by reducing admissions for uncomplicated ABSSSI while delivering comparable if not superior care for this disease, allowing optimal utilization of BJH inpatient beds for other serious medical conditions requiring inpatient care. The investigators believe this novel alternative approach will allow hospitals such as BJH to more cost-effectively and efficiently manage ABSSSI patients. This study will reduce the number of \>2 midnight observation admissions to BJH for ABSSSI, thereby improving inpatient capacity to care for patients requiring \>2 midnight hospital inpatient admission.

The investigators will conduct a randomized controlled trial comparing patients treated with a single-dose of intravenous dalbavancin (an antibiotic that has been FDA-approved for the treatment of ABSSSI and is currently being used in clinical practice in the U.S.) and discharged home from the ED with close ambulatory care follow-up in clinic vs. patients treated with "usual care" (hospital admission for multiple doses of intravenous vancomycin or other antibiotic directed towards Gram-positive bacteria). Clinical outcomes, healthcare utilization, hospital costs, and patient satisfaction will be evaluated.